1097-0215/asset/cover.gif?v=1&s=9bea5e55449dab2cff7ad3b06277cc9745417a23 "International Journal of Cancer")
The first two authors contributed equally to this paper.
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Fast Track
You have full text access to this OnlineOpen article
Mutant p53R270H gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis
Article first published online: 18 DEC 2007
DOI: 10.1002/ijc.23317
Copyright © 2007 Wiley-Liss, Inc.
Additional Information
How to Cite
Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W. and Tolstonog, G. V. (2008), Mutant p53R270H gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int. J. Cancer, 122: 1701–1709. doi: 10.1002/ijc.23317
- ‡
The first two authors contributed equally to this paper.
- §
Fax: +49-040 48051-117.
Publication History
- Issue published online: 19 FEB 2008
- Article first published online: 18 DEC 2007
- Manuscript Accepted: 29 OCT 2007
- Manuscript Received: 7 SEP 2007
Funded by
- Deutsche Forschungsgemeinschaft
- The Hamburger Stiftung zur Förderung der Krebsbekämpfung
- The Fond der Chemischen Industrie
- EC FP6 funding
- The publication reflects only the authors' views and the Community is not liable for any use that may be made of the information contained therein
- Krebsforschung International
- Freie und Hansestadt Hamburg and the Bundesministerium für Gesundheit
References
- 1,,,. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6–17.
- 2,,,. p53 mutations in human cancers. Science 1991; 253: 49–53.
- 3. Mutant p53 Oncogene, vol. 26. Oncogene. Nature publishing group, The Macmillan Building, 4 Crinan Street, London, NI 9XW, UK, 2007.
- 4,,,,,,,,,,,, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157–67.
- 5,. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 2005; 576: 4–21.
- 6
- 7,. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26: 2177–84.
- 8. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007; 17: 66–70.
- 9,,,,,,,. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 2000; 157: 2151–9.
- 10,,,,,. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 1299–303.
- 11,,,. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000; 19: 1028–37.
- 12,,,,,. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83–6.
- 13,,,,,. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene 2005; 24: 4645–59.
- 14,,,,,,,,,,,, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–70.
- 15. TP53 and breast cancer. Hum Mutat 2003; 21: 292–300.
- 16,,,,,,,,,,,. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19: 968–88.
- 17,,,,,,,,,,,. Regulation of p53 activity through lysine methylation. Nature 2004; 432: 353–60.
- 18,. Knockdown stands up. Trends Biotechnol 2003; 21: 2–4.
- 19,,,,,,,. Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56γ knockdown. Cancer Res 2004; 64: 6978–88.
- 20,. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746–55.
- 21,,,,,,. Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas 1995; 11: 213–22.
- 22,,,,. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci USA 2000; 97: 3236–41.
- 23,. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 2000; 19: 1045–51.
- 24,,,,,,,,,,,. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005; 65: 8166–73.
- 25,,,,,,,,. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469–83.
- 26,,,,,,,,,,,, et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 2007; 67: 4648–56.
- 27,,,. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 1992; 6: 1886–98.
- 28,,,. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993; 8: 2805–12.
- 29,,,,,,. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72–9.
- 30,. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J Gen Virol 1998; 79(Part 12): 3079–83.
- 31,,,,. Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. J Virol 1997; 71: 5620–3.
- 32,,,,. p53 in SV40-transformed DNA-damaged human cells binds to its cognate sequence but fails to transactivate target genes. Int J Oncol 2001; 18: 281–6.
- 33,,,. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 2002; 277: 12937–45.
- 34,,,,. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 2006; 20: 2373–82.
- 35,,,,,,,. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847–60.
- 36,,,,,,,,,,,. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861–72.
- 37. The yin and yang of p53 in cellular proliferation. Semin Cancer Biol 1994; 5: 187–202.
- 38
- 39,,. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005; 24: 7729–45.
- 40
- 41,. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217: 998–1003.
- 42,,,,,,,,,,,, et al. Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 2007; 67: 2396–401.
- 43,,,,. Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007; 35: 2093–104.
- 44,,,,,. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25: 304–9.
- 45,,. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477–85.
- 46,,. Transcription regulation by mutant p53. Oncogene 2007; 26: 2202–11.
- 47,. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26: 2220–5.
- 48,,. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007; 9: 573–80.
- 49,,,. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene 2001; 20: 2579–86.